Tioma Therapeutics, a St. Louis-based pharmaceutical discovery startup formerly known as Vasculox, has raised an $86 million round of funding led by Clayton-based RiverVest Venture Partners.
The money raised will be used to further develop Tioma’s antibody portfolio, including its lead drug candidate — an anti-CD47 immune checkpoint inhibitor. The company is focused on developing drugs for disorders including leukemia, lymphoma and solid tumors.
The company also announced that John Donovan has been hired as the company’s president and CEO. Donovan, who also sits on Tioma’s board of directors, previously served as co-founder and CFO of Alios BioPharma, which was acquired by Johnson & Johnson in 2014 for $1.75 billion.
Read more: St. Louis Business Journal